2.7. Analysis.
Comparison 2: Ivermectin for treating COVID‐19 in outpatient settings with asymptomatic or mild disease, Outcome 7: Quality of life (mental component) at up to 28 days
Comparison 2: Ivermectin for treating COVID‐19 in outpatient settings with asymptomatic or mild disease, Outcome 7: Quality of life (mental component) at up to 28 days